Clinical Trials
32 trialsParicalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Massachusetts General Hospital
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
Abramson Cancer Center at Penn Medicine
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
University of Kentucky
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
Abramson Cancer Center at Penn Medicine
Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
LY3214996 +/- HCQ in Pancreatic Cancer
Dana-Farber Cancer Institute
MEKiAUTO
Columbia University
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
Abramson Cancer Center at Penn Medicine
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
National Institutes of Health Clinical Center (CC)
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
Rutgers, The State University of New Jersey
Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II
Rutgers, The State University of New Jersey
Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer
Rutgers, The State University of New Jersey
SariPRO
Sanofi
A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy
Memorial Sloan Kettering Cancer Center
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors
University of Kentucky
17-134
University of Pittsburgh
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
University of Pittsburgh
Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
University of Pittsburgh
Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine
University of Pittsburgh
SAIL
Brigham and Women's Hospital
Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
Dana-Farber Cancer Institute
Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer
Rutgers, The State University of New Jersey
Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer
Rutgers, The State University of New Jersey
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital
Hydroxychloroquine in Untreated B-CLL Patients
Northwell Health
A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma
Shin Kong Wu Ho-Su Memorial Hospital